Premium
31 P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia
Author(s) -
Komoroski Richard A.,
Holder John C.,
Pappas Alex A.,
Finkbeiner Alex E.
Publication year - 2011
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.22677
Subject(s) - phosphocholine , phospholipid , in vivo , prostate cancer , choline , prostate , magnetic resonance spectroscopic imaging , hyperplasia , cancer , chemistry , in vitro , magnetic resonance imaging , medicine , biochemistry , biology , phosphatidylcholine , radiology , microbiology and biotechnology , membrane
1 H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline‐containing phospholipid metabolites. Although 31 P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro 31 P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the “total choline” resonance observed by 1 H MRSI in vivo. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.